Skip to content
All Podcasts – Lifestyle
Author:
ArriVent BioPharma, Inc.
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
October 23, 2026
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
October 19, 2026
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
October 12, 2026
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
October 6, 2026
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
August 12, 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 11, 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
May 7, 2026